Lucent Diagnostics has announced a partnership with Life Line Screening (LLS) to expand access to advanced blood-based diagnostic testing across the United States. The initiative aims to utilize LLS’s extensive community health network to offer Lucent’s non-invasive biomarker tests, with programs already underway in states including Florida, California, and Texas.
This collaboration addresses a critical public health need, particularly given that an estimated 7 million Americans currently live with Alzheimer’s disease, while another 6 to 7 million experience symptoms of Mild Cognitive Impairment (MCI), according to the Alzheimer’s Association. The partnership seeks to provide scalable and accessible testing options to facilitate earlier identification of cognitive diseases, which can significantly improve treatment outcomes.
“Too many chronic conditions go undetected until they become life-altering events,” stated Jim Waters, Chief Operating Officer at Life Line Screening. “By partnering with Lucent Diagnostics, we’re able to continue to expand our mission of uncovering asymptomatic risks earlier and more equitably. This partnership has the potential to impact numerous lives by supporting more informed treatment pathways, and it’s something we’re excited to bring to communities across the country.”
The testing will be available through LLS’s mobile delivery model, allowing tests to be conducted at local venues such as community centers, churches, and senior centers. Results from these tests will be shared with primary care physicians, enabling early intervention and proactive lifestyle management for adults.
“Scientific rigor shouldn’t stop at the laboratory door,” explained Zachary Fernandes, General Manager for Lucent Diagnostics at Quanterix. “Through LLS, we are bringing validated, high-quality science into community testing networks, helping ensure that everyone has access to information for use by their physician, not only in a research setting. This is a critical step toward earlier, more reliable detection of Alzheimer’s Disease.”
Life Line Screening operates throughout the 48 contiguous states, hosting over 15,000 community events annually. This extensive infrastructure enables the organization to reach individuals not only in major metropolitan areas but also in underserved rural regions.
For more information about Life Line Screening, visit their website at www.lifelinescreening.com. To learn more about Lucent Diagnostics and its parent company, Quanterix Corporation, visit www.lucentdiagnostics.com.
Lucent Diagnostics, a brand of Quanterix, was established in 2023 to deliver innovative tools that aid in the earlier detection of cognitive diseases. Utilizing the ultra-sensitive Simoa® technology, Lucent Diagnostics bridges the gap between research and clinical application, providing tailored products and services for institutions and healthcare providers. With over a decade of proven success in neurology research and supported by numerous publications, Quanterix aims to significantly impact the landscape of cognitive disease through its commercial offerings.
In summary, this partnership between Lucent Diagnostics and Life Line Screening represents a significant advancement in community health initiatives, aiming to enhance early detection and intervention for conditions like Alzheimer’s disease.
